What Is a Betamethasone Injection?

Compound betamethasone injection, the indication is suitable for the treatment of acute and chronic diseases sensitive to glucocorticoids. Glucocorticoid therapy is an adjunct to conventional therapy and cannot replace conventional therapy. Musculoskeletal and soft tissue disorders: rheumatoid arthritis, osteoarthritis, bursitis, ankylosing spondylitis, epicondylitis, spinal radiculitis, coccygeal pain, sciatica, low back pain, torticollis, tendon sheath cysts, exogenous bone Warts and fasciitis. Allergic diseases: chronic bronchial asthma (including adjuvant treatment of persistent asthma), hay fever, angioedema, allergic bronchitis, seasonal or perennial allergic rhinitis, drug reactions, serum sickness, insect bites. Skin diseases: atopic dermatitis (coin-like eczema), neurodermatitis (limited simple moss), contact dermatitis, severe solar dermatitis, urticaria, hypertrophic lichen planus, diabetic progressive necrosis, alopecia areata, discoid Lupus erythematosus, psoriasis, keloids, pemphigus, herpes-like dermatitis, cystic acne. Collagen disease: disseminated lupus erythematosus, scleroderma, dermatomyositis, nodular perivascular inflammation. Tumors: Palliative treatment of leukemia and lymphoma in adults, and acute leukemia in children. Other diseases: adrenal gonadal syndrome, ulcerative colitis, segmental ileitis, stomatitis diarrhea, foot disease (hard corneal bursitis, stiff thumb, little toe inversion), diseases requiring subconjunctival injection, Glucocorticoids work with cachexia, nephritis and nephrotic syndrome. This product can treat primary or secondary adrenal insufficiency, but mineralocorticoid should be supplemented appropriately. This product is recommended for: (1) intramuscular injection to treat diseases that are effective for systemic glucocorticoids; (2) direct injection into the soft tissue of patients with indications; (3) intraarticular and periarticular injection for arthritis (4) intradermal injection to treat various skin diseases; (5) local injection to treat certain foot inflammatory and cystic diseases.

Compound betamethasone injection, the indication is suitable for the treatment of acute and chronic diseases sensitive to glucocorticoids. Glucocorticoid therapy is an adjunct to conventional therapy and cannot replace conventional therapy. Musculoskeletal and soft tissue disorders: rheumatoid arthritis, osteoarthritis, bursitis, ankylosing spondylitis, epicondylitis, spinal radiculitis, coccygeal pain, sciatica, low back pain, torticollis, tendon sheath cysts, exogenous bones Warts and fasciitis. Allergic diseases: chronic bronchial asthma (including adjuvant treatment of persistent asthma), hay fever, angioedema, allergic bronchitis, seasonal or perennial allergic rhinitis, drug reactions, serum sickness, insect bites. Skin diseases: atopic dermatitis (coin-like eczema), neurodermatitis (limited simple moss), contact dermatitis, severe solar dermatitis, urticaria, hypertrophic lichen planus, diabetic progressive necrosis, alopecia areata, discoid Lupus erythematosus, psoriasis, keloids, pemphigus, herpes-like dermatitis, cystic acne. Collagen disease: disseminated lupus erythematosus, scleroderma, dermatomyositis, nodular perivascular inflammation. Tumors: Palliative treatment of leukemia and lymphoma in adults, and acute leukemia in children. Other diseases: adrenal gonadal syndrome, ulcerative colitis, segmental ileitis, stomatitis diarrhea, foot disease (hard corneal bursitis, stiff thumb, little toe inversion), diseases requiring subconjunctival injection, Glucocorticoids work with cachexia, nephritis and nephrotic syndrome. This product can treat primary or secondary adrenal insufficiency, but mineralocorticoid should be supplemented appropriately. This product is recommended for: (1) intramuscular injection to treat diseases that are effective for systemic glucocorticoids; (2) direct injection into the soft tissue of patients with indications; (3) intraarticular and periarticular injection for arthritis (4) intradermal injection to treat various skin diseases; (5) local injection to treat certain foot inflammatory and cystic diseases.

Drug Name

Compound Betamethasone Injection

Drug type

Prescription drugs, medicines for medical workers' injuries

Special medicine

Doping

Use classification

Hormonal antitumor drugs

Ingredients of Compound Betamethasone Injection

This product is a compound preparation, and its components are: betamethasone dipropionate and sodium betamethasone phosphate. Each containing betamethasone dipropionate is 5mg by betamethasone and sodium betamethasone phosphate is 2mg by betamethasone, and contains sterilizing buffer and preservatives. Inactive ingredients include disodium hydrogen phosphate dihydrate, sodium chloride, disodium edetate, Tween 80, benzyl alcohol, methyl parahydroxybenzoate, propyl parahydroxybenzoate, sodium carboxymethyl cellulose, polymer Ethylene glycol 3350 and water for injection.

Properties of Compound Betamethasone Injection

This product is a white suspension.

Indications of Compound Betamethasone Injection

This product is suitable for the treatment of acute and chronic diseases sensitive to glucocorticoids. Glucocorticoid therapy is an adjunct to conventional therapy and cannot replace conventional therapy.
Musculoskeletal and soft tissue disorders: rheumatoid arthritis, osteoarthritis, bursitis, ankylosing spondylitis, epicondylitis, spinal radiculitis, coccygeal pain, sciatica, low back pain, torticollis, tendon sheath cysts, exogenous bones Warts and fasciitis.
Allergic diseases: chronic bronchial asthma (including adjuvant treatment of persistent asthma), hay fever, angioedema, allergic bronchitis, seasonal or perennial allergic rhinitis, drug reactions, serum sickness, insect bites.
Skin diseases: atopic dermatitis (coin-like eczema), neurodermatitis (limited simple moss), contact dermatitis, severe solar dermatitis, urticaria, hypertrophic lichen planus, diabetic progressive necrosis, alopecia areata, discoid Lupus erythematosus, psoriasis, keloids, pemphigus, herpes-like dermatitis, cystic acne.
Collagen disease: disseminated lupus erythematosus, scleroderma, dermatomyositis, nodular perivascular inflammation.
Tumors: Palliative treatment of leukemia and lymphoma in adults, and acute leukemia in children.
Other diseases: adrenal gonadal syndrome, ulcerative colitis, segmental ileitis, stomatitis diarrhea, foot disease (hard corneal bursitis, stiff thumb, little toe inversion), diseases requiring subconjunctival injection, Glucocorticoids work with cachexia, nephritis and nephrotic syndrome.
This product can treat primary or secondary adrenal insufficiency, but mineralocorticoid should be supplemented appropriately.
This product is recommended for:
(1) Intramuscular injection to treat diseases that work for systemic glucocorticoids;
(2) Directly inject soft tissues of patients with indications;
(3) intra-articular and peri-articular injections to treat arthritis;
(4) Intralesional injection to treat various skin diseases;
(5) Local injection for the treatment of certain foot inflammatory and cystic diseases.

Specifications of Compound Betamethasone Injection

1ml: betamethasone dipropionate (as betamethasone) 5mg and betamethasone sodium phosphate (as betamethasone) 2mg.

Compound Betamethasone Injection Usage and Dosage

The required dose varies, and the dose must be individualized according to the nature, severity of the disease, and patient response.
The initial dose should be maintained or adjusted until satisfactory results are achieved. If a satisfactory clinical effect is not achieved after appropriate time treatment, this product should be discontinued and other appropriate treatment methods should be used.
Systemic administration: For most diseases, the starting dose for systemic treatment is 1 to 2 ml, which can be repeated if necessary. The method of administration is deep intramuscular injection (IM) of the buttocks. The dose and frequency of administration depend on the severity and efficacy of the disease. For patients with lupus erythematosus that has been alleviated by appropriate rescue measures, the initial dose may require 2ml.
A variety of skin diseases are effective after intramuscular injection of 1ml of this product. Repeated administration can be selected according to the condition.
In the treatment of respiratory diseases, symptoms are relieved within a few hours after intramuscular injection of this product. For bronchial asthma, hay fever, allergic bronchitis and allergic rhinitis, injecting 1 to 2 ml of this product can effectively control symptoms.
For the treatment of acute or chronic synovial bursitis, intramuscular injection of 1 to 2ml of this product is very effective, and can be repeated if necessary.
Topical use: Generally, local anesthetics are not required. For combined use, this product can be mixed with 1% or 2% procaine hydrochloride or lidocaine in a syringe (not in a medicine bottle), but it should be used without Preparation of parabens. Similar local anesthetics can also be used, but local anesthetics containing methylparaben, propylparaben and phenol cannot be used. Before use, the appropriate amount of suspension injection in the vial must be drawn into the syringe, and then Withdraw the local anesthetic and shake for a while.
In the treatment of acute sub deltoid muscle, subacromial, subhumeral, and anterior zygomatic synovial bursitis, intra-bursal injection of 1 to 2 ml of this product can relieve pain and allow unlimited movement. In the treatment of chronic bursitis, the dose can be reduced once the acute symptoms are controlled. Acute tenosynovitis, tenosynovitis, and tenosynovitis alleviate symptoms by injecting this product once. In the chronic phase of this type of disease, repeated administration may be required depending on the patient's condition.
Intra-articular injection of 0.5 to 2 ml of this product can relieve the pain, distress and stiffness associated with rheumatoid arthritis and osteoarthritis within 2 to 4 hours. The duration of remission varies widely in both diseases, most of which are more than four weeks.
Intra-articular injection of this product is well tolerated by joints and surrounding tissues. The recommended dose for intra-articular injection is 1 to 2 ml for large joints (knee, hip, shoulder); 0.5 to 1 ml for medium joints (elbow, wrist, ankle); and 0.25 to 0.5 ml for small joints (foot, hand, chest).
Intralesional injection of this product is effective for skin diseases. Some skin lesions appear to be effective without topical application, which may be due to the mild systemic effects of the drug. Intradermal injection The recommended dosage for the treatment of this product is intradermal injection of 0.2ml / cm2, which is injected with a tuberculin syringe and a 26 gauge needle. The total injection of this product in all parts should not exceed 1ml per week. This product can be effectively used for certain foot diseases that work for glucocorticoids. Each injection of 0.25ml can control hard corneal bursitis. For certain diseases such as stiff thumb, varus varus and acute gouty arthritis, symptoms can be quickly relieved. In most cases, it is suitable for injection with a tuberculin syringe and a 25 gauge needle. The following recommended doses can be used at intervals of about one week; hard corneal or soft corneal bursitis is 0.25 to 0.5ml, calcaneus spur bursitis is 0.5ml, stiff thumb bursitis is 0.5ml, and small toe inversion Bursitis is 0.5ml; bursal cysts are 0.25 to 0.5ml, Morton's neuralgia (patella pain) is 0.25 to 0.5ml, tenosynovitis is 0.5ml, periosteal periostitis is 0.5ml, and acute gouty arthritis is 0.5 to 1ml.
After a good effect is obtained, the dose should be gradually reduced from the initial dose through a suitable time interval until the dose is gradually reduced to the lowest dose that can fully achieve the clinical effect, as a maintenance amount.
When the patient is in a state of stress that is not related to the existing disease, the dosage of this product needs to be increased. If the drug needs to be discontinued after long-term treatment, it must be gradually reduced.

Adverse reactions of compound betamethasone injection

The adverse reactions of this product are similar to other adverse reactions of glucocorticoids. They are related to the dosage and the course of treatment. They can be eliminated or reduced by reducing the dosage, which is more commonly used.
Water and electrolyte disorders: sodium retention, potassium loss, hypokalemia, alkalosis, fluid retention, congestive heart failure in susceptible patients, hypertension.
Musculoskeletal: muscle weakness, glucocorticoid myopathy, muscle wasting, exacerbation of myasthenia gravis, osteoporosis, vertebral compression fractures, aseptic necrosis of the femoral and humeral head, pathological fractures of long bones Joint instability (due to repeated intra-articular injections).
Gastrointestinal tract: peptic ulcer (perforation and bleeding may occur later), pancreatitis, bloating, ulcerative esophagitis.
Skin: Affect wound healing, skin atrophy, thin and brittle skin, petechiae and ecchymosis, facial erythema, sweating, suppressed skin test response, allergic dermatitis, urticaria, angioedema.
Nervous system: convulsions, increased intracranial pressure with optic nerve papillary edema (pseudobrain tumor), dizziness, and headache.
Endocrine system: menstrual disorders, Cushing's syndrome-like manifestations, fetal intrauterine development or pediatric growth inhibition; secondary adrenal cortex and pituitary gland lack responsiveness, especially during stressful conditions, such as trauma, surgery, or disease; Impaired carbohydrate tolerance is manifested by occult diabetes, and patients with diabetes require increased insulin or oral hypoglycemic drugs. Eye; cataract under posterior capsule, increased intraocular pressure, glaucoma, exophthalmos.
Metabolic response: Negative nitrogen balance due to protein catabolism.
Mental symptoms: euphoria, mood swings, severe depression to obvious mental symptoms, personality changes, insomnia.
Others: allergic or allergic reactions and hypotension or shock-like reactions.
Other adverse reactions related to the injection of glucocorticoids include occasional blindness associated with intradermal lesions of the head and face, hyperpigmentation or hypopigmentation, subcutaneous and skin atrophy, sterile abscesses, flushing after intraarticular injection, and Charcot joint-like lesions.

Contraindications of compound betamethasone injection

Patients with systemic fungal infections and allergies to betamethasone or other glucocorticoids or any of the ingredients in this product are contraindicated.

Precautions for Compound Betamethasone Injection

This product contains benzyl alcohol, which is prohibited for intramuscular injection in children.
This product should not be given intravenously or subcutaneously.
When using this product, the aseptic operation regulations must be strictly implemented.
This product contains two kinds of betamethasone esters. Betamethasone sodium phosphate is one of them. This medicine is quickly dispersed at the injection site. For this reason, physicians should consider that the soluble ingredients contained in it may cause systemic effects when using this product.
Patients with idiopathic thrombocytopenic purpura should be cautious when injecting this product intramuscularly.
Intramuscular injection of glucocorticoids should be injected deep into large muscles to avoid local tissue atrophy.
Infusion of corticosteroids in soft tissues, skin lesions, and joints can cause local and systemic effects.
In order to rule out purulent infections, joint fluids need to be examined. Avoid local injections of drugs in joints that have had infections. Joint pain and local edema are significantly worsened, joint motion is further limited, and fever and discomfort suggest the occurrence of septic arthritis. If confirmed, appropriate antibacterial treatment should be given.
Glucocorticoids should not be injected into unstable joints, infected sites, or the occipital space. Repeated injections in joints with osteoarthritis can increase joint damage. Injecting glucocorticoids directly into the tendon can cause delayed tendon rupture, so it should be avoided.
Patients with improved symptoms after intra-articular injection of glucocorticoids should take care to avoid overuse of improved joints.
Because patients receiving glucocorticoid injections can occasionally develop allergic reactions, appropriate precautions should be taken before administration, especially for patients with a history of drug allergies. When using glucocorticoid therapy for a long time, you should consider changing the injection to oral administration after weighing the advantages and disadvantages.
The patient's condition is relieved or worsened, the patient's response to the drug and the patient's emotional or physical stress such as severe infection, surgery or trauma, and the drug dose needs to be adjusted. For long-term or high-dose glucocorticoid patients, one year of observation is required after discontinuation.
Glucocorticoids can mask some signs of infection. New infections can occur when using these drugs. At the same time, the body's resistance is weakened and the infection cannot be controlled to a limited extent.
Long-term use of glucocorticoids can produce subcapsular cataracts (especially in children) and glaucoma that may damage the optic nerve, and can promote secondary fungal or viral infections in the eye. Constant and high-dose glucocorticoids can cause elevated blood pressure, increased sodium retention and increased potassium excretion. For synthetic derivatives if not used in large doses. Such reactions are less likely to occur. Consider limiting salt and potassium supplements in your diet. Glucocorticoids can promote calcium excretion.
During glucocorticoid administration, patients should not be vaccinated against smallpox. Glucocorticoids, especially in high-dose patients, should not receive other immunotherapy because of possible neurological complications and lack of antibody responses. However, for patients receiving glucocorticoids as an alternative therapy, such as Addison's disease, immunotherapy can be performed.
Patients using glucocorticoids in immunosuppressive quantities should be wary of exposure to chicken pox or measles, and if they have, they should consult a physician. This is especially important for children. For active tuberculosis, glucocorticoid therapy should be limited to patients with fulminant or disseminated tuberculosis. Glucocorticoids should be used at the same time as appropriate anti-tuberculosis therapies.
When glucocorticoids are used in patients with tuberculosis or tuberculin-responsive patients at rest, they need to be closely observed because tuberculosis may return to activity. Patients with long-term glucocorticoid therapy should receive prophylactic chemotherapy. If rifampicin is used in the chemotherapy regimen, the promotion of liver clearance in the metabolism of glucocorticoids should be considered, and the dose of glucocorticoid may need to be adjusted.
During treatment with glucocorticoids, the minimum dose should be used in order to control the disease, and it should be gradually reduced when possible.
Drug-induced secondary adrenal insufficiency can be caused by glucocorticoid spraying too fast, which can be relieved by gradual reduction. This relative insufficiency can persist for several months after discontinuation of the drug, so if stress occurs during this period, hormone therapy should be re-administered; if the patient has been using glucocorticoids, the dose should be increased. Since mineralocorticoid secretion may be impaired, salt and / or mineralocorticoid should be given at the same time.
For patients with hypothyroidism or cirrhosis, the effects of glucocorticoids have been enhanced.
For patients with ocular herpes simplex, because corneal perforation may occur, it is recommended to use glucocorticoids with caution.
Insanity can be seen with glucocorticoid therapy. Glucocorticoids can aggravate existing emotional instability or mental illness.
Glucocorticoids should be used with caution in the following cases: nonspecific ulcerative colitis with the possibility of perforation, abscesses or other purulent infections, diverticulitis, recent small bowel anastomosis, active or occult gastric ulcer, Renal insufficiency, hypertension, osteoporosis and myasthenia gravis.
Because the complications of glucocorticoid therapy depend on the dosage and duration of the medication, each patient has to weigh the pros and cons to make a decision.
For some patients, glucocorticoids can alter sperm motility and number.
Use with caution by athletes.

Compound betamethasone injection for pregnant and lactating women

No controlled human reproduction studies have been performed on glucocorticoids, so depotrazone should only be used in pregnant women or women of childbearing age after weighing the advantages and disadvantages of the drug for the mother and fetus. Babies born to mothers who received large doses of glucocorticoids during pregnancy should carefully observe signs of adrenal insufficiency. Due to the possible adverse reactions of DuPonteson to nursing infants, the decision to discontinue or stop breastfeeding should be made when considering the importance of the drug to the mother.

Compound betamethasone injection for children

This product contains benzyl alcohol, which is prohibited for intramuscular injection in children.

Compound betamethasone injection for the elderly

Research data on medications for elderly patients are lacking.

Compound Betamethasone Injection Drug Interactions

Concomitant use of phenobarbital rifampin phenytoin or ephedrine can promote the metabolism of glucocorticoids and reduce their efficacy.
For patients who use glucocorticoid and estrogen at the same time, pay attention to observe the symptoms of excessive glucocorticoid effect.
The simultaneous use of glucocorticoids and potassium excretion diuretics can aggravate hypokalemia; the simultaneous use of glucocorticoids and cardiac glycosides may increase the risk of arrhythmia or digitalis poisoning associated with hypokalemia; glucocorticoids Hormonal drugs can promote potassium loss caused by amphotericin B. Close monitoring of serum electrolytes, especially serum potassium levels, is required for all patients using any of these combinations.
The simultaneous use of glucocorticoids and coumarin anticoagulants can increase or decrease the anticoagulant effect and therefore may need to be adjusted.
Non-steroidal anti-inflammatory drugs or ethanol in combination with glucocorticoids can increase the incidence or worsen gastrointestinal ulcers.
Glucocorticoids can reduce blood salicylate concentrations. Caution should be used in patients with too little prothrombin when using aspirin in combination with glucocorticoids.
Administering glucocorticoids to diabetic patients may require adjustments to the amount of antidiabetic drugs.
Concomitant use of glucocorticoid therapy can inhibit the body's response to growth hormone.
Drug / Laboratory Interactions: Glucocorticoids may affect false negative results in the tetrazolium blue test for bacterial infections.

Compound betamethasone injection overdose

Symptoms: Acute overdose of glucocorticoids, including betamethasone, generally does not cause life-threatening conditions. Except for very large doses, patients who do not have specific contraindications will rarely experience adverse reactions if they overuse glucocorticoids for several days. Special contraindications are patients with diabetes, glaucoma, active peptic ulcers, digitalis, coumarin anticoagulants or potassium-releasing diuretics.
Treatment: For the metabolic effects of glucocorticoids or the harmful effects of basic lesions or miscellaneous diseases or complications caused by drug interactions, appropriate treatment should be made. Patients should maintain sufficient body fluid intake, monitor serum and urine electrolytes, paying particular attention to potassium and sodium balance. If necessary, treat electrolyte disorders.

Pharmacology and Toxicology of Compound Betamethasone Injection

This product is a compound preparation of soluble betamethasone and slightly soluble betamethasone, which can exert strong anti-inflammatory, anti-rheumatic and anti-allergic effects in the treatment of diseases that work for glucocorticoids. Soluble Betamethasone Sodium Phosphate is absorbed quickly after injection and has a rapid onset of action. After injection of the slightly soluble betamethasone dipropionate, it becomes a depot for slow absorption, which continues to work, thereby controlling symptoms for a long time. Betamethasone dipropionate has a small grain size and can be administered by intradermal and intralesional injection through small needles (up to 26 gauge needles).
Glucocorticoids such as betamethasone can cause a variety of obvious metabolic reactions and change the body's immune response to various stimuli.
Betamethasone has high glucocorticoid activity and mild mineralocorticoid activity.

Pharmacokinetics of Compound Betamethasone Injection

Betamethasone sodium phosphate and betamethasone dipropionate are absorbed at the injection site and exert therapeutic and other local and systemic pharmacological effects.
Betamethasone sodium phosphate is soluble in water and is metabolized to betamethasone in tissues. The biological effect of 2.63mg betamethasone sodium glucocorticoid is equivalent to 2mg betamethasone. Betamethasone dipropionate makes the drug lasting. Because this ingredient is slightly soluble, it slows down absorption, which can reduce symptoms for a long time.

Betamethasone is metabolized by the liver, which mainly binds to proteins. Slower or delayed clearance may occur in patients with liver disease.

Storage of compound betamethasone injection

Protect from light and store at 2-25 ° C.

Package of compound betamethasone injection

Glass ampoules, 1 stick / box.

Validity of Compound Betamethasone Injection

24 months

Compound Betamethasone Injection Standard

Import drug registration standard JX20070074 ^[1]